Physician

Alison Sehgal

According to 2025 Medicare claims, Alison Sehgal (NPI: 1750584140) practices hematology in the Pittsburgh, PA market, with the plurality of this provider's patient population coming from Allegheny, PA. This provider's primary affiliated billing organization is ONCOLOGY HEMATOLOGY ASSOCIATION INC (NPI: 1861469223; TIN: 251762980) and primary practice location at 15232-1301.

Sehgal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 185 traditional Medicare patients, billed 724 HCPCS/CPT codes, and received $51,420 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 778 prescription claims across 98 beneficiaries totaling $1,569,756 in drug costs, led by Pomalyst (Pomalidomide). 2019 DME data shows 12 claims. Open Payments data shows 12 records totaling $28,792. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $29,904 to $51,420. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	91	432	$29,904
2016	99	374	$25,709
2017	136	645	$45,001
2018	142	668	$47,471
2019	146	538	$36,769
2020	159	539	$34,015
2021	180	600	$45,527
2022	189	668	$48,643
2023	198	606	$48,111
2024	185	724	$51,420

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	50	345	$294,331
2016	64	422	$707,058
2017	69	744	$1,612,973
2018	81	912	$1,983,369
2019	115	1,104	$2,594,986
2020	94	952	$2,782,258
2021	114	943	$3,510,418
2022	128	1,103	$4,076,564
2023	110	859	$1,926,721
2024	98	778	$1,569,756

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	12	$323
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	47	108	$101
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	43	227	$89
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	93	147	$64
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	35	87	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	60	95	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	15	420	$341,952
Bosulif	Bosutinib	13	390	$227,076
Calquence	Acalabrutinib Maleate	12	360	$184,866
Sprycel	Dasatinib	11	330	$158,411
Venclexta	Venetoclax	20	390	$141,218

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	0	$0	N/R
Research Payments	Reported research-related payment or transfer-of-value amount.	12	$28,792	Kite Pharma, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alison Sehgal?

Tedicare shows public-source Medicare data for Alison Sehgal (NPI 1750584140), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alison Sehgal have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alison Sehgal?

Alison Sehgal is linked to ONCOLOGY HEMATOLOGY ASSOCIATION INC (billing NPI 1861469223) in the available physician profile data.

Does Alison Sehgal have Open Payments data?

Alison Sehgal has 12 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.